Will provide expertise across ModeX’s portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer ModeX’s promising immunology pipeline includes first-in class drugs with two assets in ongoing clinical trials and multiple pre-IND assets to enter clinical trials WESTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the creation of a Scientific Advisory Board to provide counse ...

OPKO Health (OPK) 2025 Conference June 04, 2025 11:05 AM ET Speaker0 Yep. I'm good. Speaker1 Good back. Okay. Hi, everyone. My name is Maury Raycroft and one of the biotech analysts at Jefferies. So it's a great pleasure that I'd like to welcome the team from OpCo. We've got Elliot Serhouni, president, and then Adam Logel, CFO. Thanks so much for joining us today. We're going to do a fireside chat format. So maybe to start things off for those who are new to the company, you can give a one minute intro to O ...

OPKO Health (OPK) FY 2025 Conference May 20, 2025 09:00 AM ET Speaker0 H. C. Wainwright's Third Annual Bioconector Investor Conference at NASDAQ. My name is Yi Chen. I'm an equity research analyst at H. C. Wainwright. For this session, we are delighted to have Mr. Elias Zahoni, president and vice chairman of OpcoHealth, and mister Evan Logo, senior vice president and chief financial officer of Opco join us for our fight Fireside Chat. Thank you for joining. Speaker1 Well, thank you for having us. Speaker0 T ...

Contacts: Alliance Advisors IR Yvonne Briggs, 310-691-7100 ybriggs@allianceadvisors.com or Bruce Voss, 310-691-7100 bvoss@allianceadvisors.com H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors and will participate in a fireside discussion at 9:00 a.m. Eastern time. Jefferies Global Healthcare Conference, June 3-5 at the Marriott Marquis in New York City. Management will hold one-on-one meetings with investors ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 75-2402409 (State or Ot ...

OPKO Health, Inc. (OPK) delivered a loss per share of 10 cents in the first quarter of 2025, narrower than the year-ago period’s loss of 12 cents per share. However, the metric was wider than the Zacks Consensus Estimate of a loss of 6 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)OPK’s Revenues in DetailOPKO Health registered revenues of $149.9 million in the first quarter, down 13.7% year over year. The figure missed the Zacks Consensus Estimate by 8.9%.The over ...

For the quarter ended March 2025, OPKO Health (OPK) reported revenue of $149.9 million, down 13.7% over the same period last year. EPS came in at -$0.10, compared to -$0.12 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $164.48 million, representing a surprise of -8.87%. The company delivered an EPS surprise of -66.67%, with the consensus EPS estimate being -$0.06.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...

OPKO Health (OPK) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -66.67%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.11 per share when it actually produced earnings of $0.01, delivering a surpr ...

OPKO Health (OPK) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Yvonne Briggs - Investor Relations and Corporate Development ExecutivePhillip Frost - Chairman & CEOElias Zerhouni - President & Vice ChairmanAdam Logal - SVP & CFOJeffrey Cohen - MD - Equity ResearchBilly Smith - Equity ResearchMichael Petusky - Managing Director Conference Call Participants James Stamos - AnalystYi Chen - Managing Director & Senior AnalystEdward Tenthoff - Sr. Research AnalystYale Jen - Senior Managing ...

OPKO Health (OPK) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good afternoon and welcome to the UpcoHealth First Quarter twenty twenty five Financial Results Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead. Speaker1 Thank you, operator. Good afternoon. This is Yvonne Briggs with Allianc ...